Sure makes you wonder about the combination study of Panzem NCD with Avastin in metastatic carcinoid tumors. Didn't Burns convienently skip it in his last presentation?
From what I understand, the trial is currently still enrolling.
If they started enrolling immediately (May 2006), we could have some interim trial results.
I'd love to see CELG and DNA get in to a bidding war for Entremed..... Some pretty deep pockets.
Market Data 
Markets 
